×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Section 143: Longitudinal Biomarker Monitoring Protocol in C
therapeutic
1,389 words
KG: ent-dise-bfd8f32d
2026-03-24
section:therapeutics
kind:therapeutic
topic:cbs
topic:psp
topic:biomarkers
topic:longitudinal-monitoring
topic:p-tau217
topic:nfl
topic:gfap
topic:disease-progression
Contents
Section 143: Longitudinal Biomarker Monitoring Protocol in CBS/PSP
💊
Therapeutic Info
Name
Section 143: Longitudinal Biomarker Monitoring Protocol in CBS/PSP
Summary
Biomarker monitoring schedule, tracking p-tau217, NfL, GFAP over time, interpretation algorithms for CBS/PSP, treatment response monitoring, disease progression tracking
Knowledge Graph
Related Hypotheses (5)
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon
Score: 0.42
Heterogeneous astrocyte activation states differentially imp
Score: 0.52
Astrocyte-Mediated Microglial Memory Erasure
Score: 0.46
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.45
Related Analyses (6)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 1 more
Related Experiments (14)
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Show 9 more